28 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
2
Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.
Tsinghua University
2
Structural requirements of acylated Gly-l-Ala-d-Glu analogs for activation of the innate immune receptor NOD2.
University of Ljubljana
19
Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.
University of Kansas
20
Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway.
University of Ljubljana
32
Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists.
University of Ljubljana
37
4-Anilinoquinazoline Derivatives as the First Potent NOD1-RIPK2 Signaling Pathway Inhibitors at the Nanomolar Range.
Univ. Lille
51
Selectively Antagonizing the NOD1-Mediated Inflammatory Signaling Pathway Mitigates the Gastric Inflammation Induced by Helicobacter pylori Infection.
Tsinghua University
1
Structure-activity relationship in NOD2 agonistic muramyl dipeptides.
Panjab University
10
Discovery of 2,3-Diaminoindole Derivatives as a Novel Class of NOD Antagonists.
University of Naples "Federico II"
2
Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis.
Shenzhen Salubris Pharmaceuticals Co.
27
Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency.
University of Ljubljana
4
Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators.
University of Ljubljana
27
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
University of Ljubljana
28
Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.
University of Houston
18
Identification of benzofused five-membered sultams, potent dual NOD1/NOD2 antagonists in vitro and in vivo.
Peking Union Medical College
30
Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.
University of Houston
15
Structural features and functional activities of benzimidazoles as NOD2 antagonists.
University of Ljubljana
29
Nonpeptidic quinazolinone derivatives as dual nucleotide-binding oligomerization domain-like receptor 1/2 antagonists for adjuvant cancer chemotherapy.
Peking Union Medical College
9
Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2.
University of Ljubljana
3
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
3
Modulation of the NOD-like receptors NOD1 and NOD2: A chemist's perspective.
University of Delaware
14
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
University of Ljubljana
32
Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.
Peking Union Medical College
26
Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
Bristol Myers Squibb
337
Heterocyclic modulators of lipid synthesis and combinations thereof
3-V Biosciences